{"id":2074,"date":"2020-04-03T16:30:20","date_gmt":"2020-04-03T20:30:20","guid":{"rendered":"https:\/\/bridgebioprod.wpengine.com\/?p=2074"},"modified":"2022-06-23T11:31:24","modified_gmt":"2022-06-23T15:31:24","slug":"bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5","status":"publish","type":"post","link":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/","title":{"rendered":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"\r\n<p>PALO ALTO, Calif., April 3, 2020 &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 31, 2020, the compensation committee of BridgeBio\u2019s board of directors granted six employees options to purchase an aggregate of 52,916 shares of the Company\u2019s common stock with a per share exercise price of $25.08 and restricted stock units for an aggregate of 22,993 shares of the Company\u2019s common stock. All of the above-described awards were made under BridgeBio\u2019s 2019 Inducement Equity Plan (the Plan).<\/p>\r\n\r\n\r\n\r\n<p>The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio\u2019s board of directors in November 2019.<\/p>\r\n\r\n\r\n\r\n<p><strong>About BridgeBio<\/strong><\/p>\r\n\r\n\r\n\r\n<p>BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio\u2019s pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.<\/p>\r\n\r\n\r\n\r\n<p><strong>Media Contact:<br \/><\/strong>Grace Rauh<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I1UvdWFu9E6zR5LihmNuSOlR4mUuKLOnccRynXRmMp1y3Zivw6HhTYOvLSNDb6YoR8y8Yqn782EVcVlveWIAMJS7arKQrcvRnA2_ORt8eJU=\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Grace.rauh@bridgebiodev.wpengine.com<\/strong><\/a><strong><br \/><\/strong>(917) 232-5478<\/p>\r\n\r\n\r\n\r\n<p><strong>Investor Contact:<br \/><\/strong>John Grimaldi, Burns McClellan<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iuCth1bTiuYavvzcBQjpcqvJ9Jwe42r8jyDuW5CWNhEaHnr9xGZrfHVuiufK4gXJ19DhGCVDXs-lHR4knFiGCuUUhUevwwQKkBrBdOzlh6Y=\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>jgrimaldi@burnsmc.com<\/strong><\/a><strong><br \/><\/strong>212-213-0006 ext. 362<\/p>\r\n\r\n\r\n\r\n<p>Source: BridgeBio Pharma, Inc.<\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, Calif., April 3, 2020 &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 31, 2020, the compensation committee of BridgeBio\u2019s board of directors granted six employees options to purchase an aggregate of 52,916 shares of the Company\u2019s common stock with a per share [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[10],"tags":[],"class_list":["post-2074","post","type-post","status-publish","format-standard","hentry","category-press-release"],"acf":{"external_link":"","presentation":"","meta_short_title":"BridgeBio Reports Inducement Grants","meta_description":"","meta_share_image":false,"people":false},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Inducement Grants | 4\/3\/20 | BridgeBio<\/title>\n<meta name=\"description\" content=\"BridgeBio announced that on March 31, 2020, the compensation committee granted six employees options to purchase an aggregate of 52,916 shares.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inducement Grants | 4\/3\/20 | BridgeBio\" \/>\n<meta property=\"og:description\" content=\"BridgeBio announced that on March 31, 2020, the compensation committee granted six employees options to purchase an aggregate of 52,916 shares.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-03T20:30:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-23T15:31:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Brandon Keller\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brandon Keller\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/\",\"url\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/\",\"name\":\"Inducement Grants | 4\/3\/20 | BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2020-04-03T20:30:20+00:00\",\"dateModified\":\"2022-06-23T15:31:24+00:00\",\"author\":{\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/6cd954001e2cec42c2e8290f7c570325\"},\"description\":\"BridgeBio announced that on March 31, 2020, the compensation committee granted six employees options to purchase an aggregate of 52,916 shares.\",\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/6cd954001e2cec42c2e8290f7c570325\",\"name\":\"Brandon Keller\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3f5f406075c438807a4d70dccadd771a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3f5f406075c438807a4d70dccadd771a?s=96&d=mm&r=g\",\"caption\":\"Brandon Keller\"},\"url\":\"https:\/\/bridgebio.com\/author\/bkeller\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inducement Grants | 4\/3\/20 | BridgeBio","description":"BridgeBio announced that on March 31, 2020, the compensation committee granted six employees options to purchase an aggregate of 52,916 shares.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/","og_locale":"en_US","og_type":"article","og_title":"Inducement Grants | 4\/3\/20 | BridgeBio","og_description":"BridgeBio announced that on March 31, 2020, the compensation committee granted six employees options to purchase an aggregate of 52,916 shares.","og_url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/","og_site_name":"BridgeBio","article_published_time":"2020-04-03T20:30:20+00:00","article_modified_time":"2022-06-23T15:31:24+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"author":"Brandon Keller","twitter_card":"summary_large_image","twitter_creator":"@BridgeBioPharma","twitter_site":"@BridgeBioPharma","twitter_misc":{"Written by":"Brandon Keller","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/","url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/","name":"Inducement Grants | 4\/3\/20 | BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2020-04-03T20:30:20+00:00","dateModified":"2022-06-23T15:31:24+00:00","author":{"@id":"https:\/\/bridgebio.com\/#\/schema\/person\/6cd954001e2cec42c2e8290f7c570325"},"description":"BridgeBio announced that on March 31, 2020, the compensation committee granted six employees options to purchase an aggregate of 52,916 shares.","breadcrumb":{"@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/6cd954001e2cec42c2e8290f7c570325","name":"Brandon Keller","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3f5f406075c438807a4d70dccadd771a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3f5f406075c438807a4d70dccadd771a?s=96&d=mm&r=g","caption":"Brandon Keller"},"url":"https:\/\/bridgebio.com\/author\/bkeller\/"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/2074"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=2074"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/2074\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=2074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/categories?post=2074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/tags?post=2074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}